Comparable stake leader
Richard K. Crumly
SEC ownership of bioAffinity Technologies, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001712762.
Disclosed value leader
Gary D. Rubin
Comparable rows
16/35
Latest evidence
31 Mar 2026
- Public ticker
- BIAF, BIAFW on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Richard K. Crumly
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
16 of 35
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Richard K. Crumly
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001712762
- Issuer location
- San Antonio, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of bioAffinity Technologies, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Richard K. Crumly
Disclosed value leader
Gary D. Rubin
Comparable rows
16/35
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 11%
19 rows are not safely comparable across share classes.
13D/G row: Richard K. Crumly
Showing 1-8 of 35 holder rows.
Quick read
Richard K. Crumly leads the comparable SEC ownership view at 11%.
16 of 35 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Richard K. Crumly's linked filing trail.
Comparable ownership
Top 5
Richard K. Crumly
11%
BIGGER CAPITAL FUND L P
5.8%
Roberto Rios
0%
VANGUARD CAPITAL MANAGEMENT LLC
2.7%
GEODE CAPITAL MANAGEMENT, LLC
2.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 35 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Richard K. Crumly |
13D/G
|
11%
|
$1,446,200
3,213,777 shares
|
$0 | 07 May 2025 |
| BIGGER CAPITAL FUND L P |
13D/G
Bigger Michael
|
5.8%
|
—
117,364 shares
|
$0 | 29 Sep 2025 |
| Roberto Rios |
3/4/5
Director
|
0%
|
$208
833 shares
|
— | 12 Aug 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
2.7%
|
$212,730
55,543 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
2.4%
|
$184,961
48,293 shares
|
— | 31 Mar 2026 |
| J. Safra Sarasin Holding AG |
13F
Company
|
2.1%
|
$164,010
42,600 shares
|
— | 31 Mar 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
1.5%
|
$119,002
31,071 shares
|
— | 31 Mar 2026 |
| Schonfeld Strategic Advisors LLC |
13F
Company
|
1.2%
|
$93,500
24,413 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 18 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to bioAffinity Technologies, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Gary D. Rubin
Net 12M change
$0
Latest report
12 Aug 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Gary D. Rubin | Director, 10%+ Owner | $4,586,464 | Mixed | 01 Jul 2024 | ||
| Steven Girgenti | Executive Chairman, Director | $2,846,638 | Mixed | 10 Jan 2025 | ||
| Nathan M. Perlmutter | 10%+ Owner | $2,213,386 | Mixed | 06 Sep 2022 | ||
| Roby Joyce | Director | $1,721,825 | Mixed | 01 Jul 2024 | ||
| Maria Zannes | President & CEO, Director | $644,803 | Mixed | 10 Jan 2025 | ||
| Robert A. Anderson | Director | $434,430 | Mixed | 01 Jul 2024 | ||
| Peter S. Knight | Director | $311,256 | Mixed | 01 Jul 2024 | ||
| James Michael Edwards | VP and CFO | $301,983 | Mixed | 10 Jan 2025 | ||
| Stuart Diamond | Director | $262,583 | Mixed | 01 Jul 2024 | ||
| Mohsin Y. Meghji | Director | $162,411 | Mixed | 01 Oct 2023 | ||
| Jamie Platt | Director | $145,082 | Mixed | 01 Jul 2024 | ||
| Michael Philip Dougherty | Chief Financial Officer | $124,620 | Mixed | 31 Jan 2024 | ||
| Timothy P. Zannes | Secretary, EVP, Gen. Counsel | $119,000 | Mixed | 10 Jan 2025 | ||
| Vivienne I. Rebel | Chief Sci. & Med. Officer, EVP | $68,417 | Mixed | 31 Jan 2024 | ||
| Xavier T. Reveles | Chief Operating Officer | $30,102 | Mixed | 10 Jan 2025 | ||
| Roberto Rios | Director | $208 | Mixed | 12 Aug 2025 | ||
| John J. Oppenheimer | Director | Mixed | 12 Aug 2025 |
Recent insider transactions for bioAffinity Technologies, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Roberto Rios | BIAF | Common Stock | 0 | 833 | 12 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.